Showing session: reset
New Drugs on the Horizon 1
- Sort by:
- Browse by:
- Permission not
granted for presentation
AZD4573: A potent and selective CDK9 inhibitor for the treatment of hematological malignancies
Lisa Drew
AstraZeneca R&D Boston, Waltham, MA, United States
- Free
- slides video
- audio + slides
- All slides included
The discovery of BT1718: A novel bicyclic peptide drug conjugate drug conjugate for the treatment of solid tumors expressing MT1-MMP
Nicholas J Keen
Bicycle Therapeutics, Lexington, MA, United States
- Free
- slides video
- audio + slides
- All slides included
FPA150: Arecombinant, afucosylated, fully human IgG1 monoclonal antibody for the treatment of malignancies that express high levels of B7-H4
Charles D Kaplan
Five Prime Therapeutics, South San Francisco, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor
Darrin D Stuart
Novartis Institutes for Biomedical Research, Cambridge, MA, United States
- Free
- slides video
- audio + slides
- All slides included
ABBV-744: A first-in-class highly BDII-selective BET bromodomain inhibitor
Warren Kati
AbbVie, North Chicago, IL, United States